Elimination kinetics of cephapirin sodium in milk after an 8-day extended therapy program of daily intramammary infusion in healthy lactating Holstein-Friesian cows

被引:6
作者
Gorden, P. J. [1 ]
van der List, M. [2 ]
Lehman, F. D. [2 ]
Lantz, R. K. [3 ]
Constable, P. D. [4 ]
机构
[1] Iowa State Univ, Dept Vet Diagnost & Prod Anim Med, Ames, IA 50011 USA
[2] Boehringer Ingelheim Vetmedica Inc, St Joseph, MO 64506 USA
[3] Rocky Mt Instrumental Labs, Ft Collins, CO 80525 USA
[4] Purdue Univ, Dept Vet Clin Sci, W Lafayette, IN 47907 USA
关键词
mastitis; gram positive; minimum inhibitory concentration; MINIMUM INHIBITORY CONCENTRATIONS; DAIRY-COWS; ANTIMICROBIAL SUSCEPTIBILITY; CLINICAL MASTITIS; BOVINE MASTITIS; STAPHYLOCOCCUS-AUREUS; SUBCLINICAL MASTITIS; MAMMARY-GLANDS; PATHOGENS; EFFICACY;
D O I
10.3168/jds.2012-6487
中图分类号
S8 [畜牧、 动物医学、狩猎、蚕、蜂];
学科分类号
0905 ;
摘要
The objective of this study was to determine the elimination kinetics of extended therapy with intramammary (IMM) cephapirin in lactating dairy cattle. Eight healthy Holstein-Friesian cows were administered cephapirin (200 mg) into all 4 mammary glands every 24 h after milking. Cows were milked 3 times per day and concentrations of cephapirin and desacetyl cephapirin were determined in bucket milk using liquid chromatography-mass spectrometry. Milk concentration-time data after the last of the 8 IMM infusions were fitted using compartment and noncompartmental models. The maximum cephapirin concentration was 128 +/- 57 mu g/mL (mean +/- SD), the elimination rate constant from the central compartment was 0.278 +/- 0.046 (h(-1)), clearance was 0.053 +/- 0.023 L/h, the half time for elimination was 2.55 +/- 0.40 h, and the mean residence time was 2.65 +/- 0.79 h. The cephapirin concentration was below the approved tolerance in all cows by 96 h after the last infusion, which is the labeled withholding time for the preparation used. Extended therapy for 8 d provided milk cephapirin concentrations above the minimum inhibitory concentration for common gram-positive mastitis pathogens (0.1 to 1.0 mu g/mL) for the duration of therapy and for an additional 16 to 32 h after the end of treatment. Our findings suggest that this IMM cephapirin sodium formulation, which is labeled for 2 doses 12 h apart, could be administered at a 24-h interval for up to 8 d in cows milked 3 times per day, with no significant effect on residue levels by 96 h after the last treatment. Longer withdrawal times would be prudent for cows with low milk production.
引用
收藏
页码:4455 / 4464
页数:10
相关论文
共 36 条
[1]   Relationship between in vitro susceptibility test results and treatment outcomes for gram-positive mastitis pathogens following treatment with cephapirin sodium [J].
Apparao, M. D. ;
Ruegg, P. L. ;
Lago, A. ;
Godden, S. ;
Bey, R. ;
Leslie, K. .
JOURNAL OF DAIRY SCIENCE, 2009, 92 (06) :2589-2597
[2]   Invited review:: The role of cow, pathogen, and treatment regimen in the therapeutic success of bovine Staphylococcus aureus mastitis [J].
Barkema, H. W. ;
Schukken, Y. H. ;
Zadoks, R. N. .
JOURNAL OF DAIRY SCIENCE, 2006, 89 (06) :1877-1895
[3]   Cefoperazone sodium preparation behavior after intramammary administration in healthy and infected cows [J].
Cagnardi, P. ;
Villa, R. ;
Gallo, M. ;
Locatelli, C. ;
Carli, S. ;
Moroni, P. ;
Zonca, A. .
JOURNAL OF DAIRY SCIENCE, 2010, 93 (09) :4105-4110
[4]   Treatment of clinical mastitis using antimicrobial susceptibility profiles for treatment decisions [J].
Constable, PD ;
Morin, DE .
VETERINARY CLINICS OF NORTH AMERICA-FOOD ANIMAL PRACTICE, 2003, 19 (01) :139-+
[5]   Use of antimicrobial susceptibility testing of bacterial pathogens isolated from the milk of dairy cows with clinical mastitis to predict response to treatment with cephapirin and oxytetracycline [J].
Constable, PD ;
Morin, DE .
JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2002, 221 (01) :103-108
[6]   Factors affecting cure and somatic cell count after pirlimycin treatment of subclinical mastitis in lactating cows [J].
Deluyker, HA ;
Van Oye, SN ;
Boucher, JF .
JOURNAL OF DAIRY SCIENCE, 2005, 88 (02) :604-614
[7]  
EMEA (European Agency for the Evaluation of Medicinal Products), 2008, EMEACVMP47398FINAL
[8]  
Erskine R., 2004, NMC Annual Meeting Proceedings, P400
[9]  
FDA (Food and Drug Administration), 2008, GL48 FDA VICH
[10]   An overview of factors affecting the disposition of intramammary preparations used to treat bovine mastitis [J].
Gehring, R ;
Smith, GW .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2006, 29 (04) :237-241